In this review:
This review discusses evidence in support of the use of mepolizumab (NUCALA®) for the treatment of severe eosinophilic asthma. Following earlier worldwide approvals, mepolizumab was licensed for use in New Zealand in June 2017 as an add-on treatment for severe refractory eosinophilic asthma in patients aged ≥12 years.1 It is the first treatment to be approved for this specific type of asthma, although it is not yet funded by PHARMAC. This publication has been commissioned by GlaxoSmithKline NZ Limited.
Please login below to download this issue (PDF)